Overview

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Alzheimer's Disease Cooperative Study (ADCS)